Polysaccharide Patents (Class 514/54)
-
Patent number: 11925669Abstract: Herbal composition having an effect of reducing uric acid, which is made from the following herbal materials in specified portions by weight: 4-30 portions of Glabrous greenbrier rhizome, 2-15 portions of Chicory, 2-15 portions of Herba Plantaginis, 2-20 portions of Coix seed, and 2-10 portions of Kudzuvine Root. The composition may be used in combination with modern Western medicines to achieve optimal effects.Type: GrantFiled: December 30, 2013Date of Patent: March 12, 2024Assignee: INFINITUS (CHINA) COMPANY LTD.Inventors: Xiaofei Xu, Xiaolei Guo, Chungwah Ma, Bin Shi, Zhen Luo
-
Patent number: 11903964Abstract: The present disclosure generally relates to a fish feed or fish feed product including a binding agent that increases the particle size and stability of feces produced by fish that consume the fish feed or fish feed product. In general, the fish feed will include a binding against such as locust bean gum, cassia gum, xanthan gum, tara gum, or combinations thereof. Also provided are methods for increases fish feces stability and methods for eliminating suspended solids from a recirculating aquaculture system.Type: GrantFiled: August 8, 2022Date of Patent: February 20, 2024Assignee: CAN TECHNOLOGIES, INC.Inventors: Dominic Andre Nanton, Peter Bjorn Rugroden, Kari Juhani Ruohonen, Marc Turano, Terje Utne
-
Patent number: 11898185Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.Type: GrantFiled: October 24, 2017Date of Patent: February 13, 2024Assignee: Chr Hansen HMO GmbHInventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
-
Patent number: 11890373Abstract: The present invention relates to delivery devices adapted to mechanically dilate a pelvic anatomical canal, the delivery devices comprise a composition formulated as a gel comprising a beneficial or therapeutic agent, said delivery devices being capable of releasing the beneficial or therapeutic agent into the pelvic anatomical canal, specifically into the vaginal canal, and thereby treat vaginal conditions associated with vaginal narrowing, atrophy, or dryness.Type: GrantFiled: March 11, 2019Date of Patent: February 6, 2024Assignee: AQUAFIT INTIMATE LTD.Inventors: Rebecca Sternberg, Vered Italiano, Varda Messer
-
Patent number: 11883103Abstract: Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including a head mounted display to monitor one or more physiologic signals from the face or head of the subject is disclosed. A method for analyzing an ocular parameter of the subject to determine a sympathetic and a parasympathetic outflow thereto is disclosed.Type: GrantFiled: August 28, 2020Date of Patent: January 30, 2024Assignee: Autonomix Medical, Inc.Inventors: Landy Toth, Robert S. Schwartz
-
Patent number: 11857564Abstract: Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.Type: GrantFiled: December 13, 2017Date of Patent: January 2, 2024Assignee: Omrix Biopharmaceuticals Ltd.Inventors: Tamar Auerbach-Nevo, Tali Negreanu-Gilboa, Hadas Alperin, Israel Nur
-
Patent number: 11839626Abstract: Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of a polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent.Type: GrantFiled: September 1, 2017Date of Patent: December 12, 2023Assignee: ROCHAL TECHNOLOGIES LLCInventors: Joseph Charles Salamone, Katelyn Elizabeth Reilly, Ronald Thomas Nixon, Ann Beal Salamone, Kelly Xiaoyu-Chen Leung
-
Patent number: 11839680Abstract: A cosmetic or dermocosmetic agent consisting of: galactomannans having molecular weights between 5 and 630 kDa, and crosslinked sulfated galactans having molecular weights between 7 and 3000 kDa. Methods of using the agent, including for skin tensing and rejuvenation.Type: GrantFiled: January 27, 2017Date of Patent: December 12, 2023Assignee: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUEInventor: Jean Paufique
-
Patent number: 11815435Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.Type: GrantFiled: February 23, 2018Date of Patent: November 14, 2023Assignee: HiberCell, Inc.Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
-
Patent number: 11806402Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.Type: GrantFiled: September 15, 2020Date of Patent: November 7, 2023Assignee: CyDex Pharmaceuticals, Inc.Inventor: Vincent D. Antle
-
Patent number: 11793762Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.Type: GrantFiled: July 28, 2020Date of Patent: October 24, 2023Inventors: Soonkap Hahn, Gantumur Battogtokh, Oyuntuya Gotov, Gil Man Kim, Min Hyo Seo
-
Patent number: 11766450Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.Type: GrantFiled: March 8, 2021Date of Patent: September 26, 2023Assignee: PT. Sahabat Lingkungan HidupInventors: Peter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
-
Patent number: 11767374Abstract: A preparation of a homogeneous polysaccharide from a Radix Puerariae aqueous extract is provided and the lipid-lowering activity of the polysaccharide is studied. It is proved through in vivo experiments that the homogeneous polysaccharide QL extracted from Radix Puerariae (a genuine medicinal material in Jiangxi Province) in the present disclosure has significant lipid-lowering activity, can significantly reduce a serum triglyceride content and a liver index, and can be used to develop a potential safe and effective lipid-lowering drug.Type: GrantFiled: March 8, 2021Date of Patent: September 26, 2023Assignee: JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINEInventors: Hui Ouyang, Quan Wen, WeiFeng Zhu, YuLin Feng, RongHua Liu, YongMei Guan, Kai Qian, Hui Du
-
Patent number: 11744847Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.Type: GrantFiled: January 22, 2021Date of Patent: September 5, 2023Assignee: KEMIN INDUSTRIES, INC.Inventors: Geoffrey Paul Horst, Robert Bernard Levine
-
Patent number: 11730786Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.Type: GrantFiled: July 24, 2020Date of Patent: August 22, 2023Assignee: WORLD FORCE TECHNOLOGIES, LLCInventors: Thomas W. Konowalchuk, Jack Konowalchuk
-
Patent number: 11732060Abstract: A crosslinked polymeric network is disclosed. The crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan.Type: GrantFiled: January 10, 2020Date of Patent: August 22, 2023Assignee: BAUSCH & LOMB INCORPORATEDInventors: George L. Grobe, III, Alok Kumar Awasthi, Mark R. Mis, Jennah L. Wolcott, James R. Hauenstein
-
Patent number: 11701381Abstract: A composition for the prevention and treatment of the oral cavity comprising hyaluronic acid and a Manuka-derived product is described. The composition of the invention stabilizes the hyaluronic acid protecting the same from the aggression of the hyaluronidase present in the oral cavity, in particular on the mucous membranes and on the gingival walls, thus increasing the overall efficacy and the therapeutic effect.Type: GrantFiled: September 13, 2019Date of Patent: July 18, 2023Assignee: FADIM LtdInventor: Andrea Dalseno
-
Patent number: 11701453Abstract: Disclosed is a method for filling a root canal in a tooth. The method includes positioning a fiber in the root canal of the tooth, filling at least a portion of the root canal with an unset hydrogel composition, such that the unset hydrogel composition contacts at least a portion of the fiber, setting the hydrogel composition, thereby forming a set hydrogel, and removing the fiber from the set hydrogel, thereby leaving a channel in the set hydrogel. Methods and kits for repairing teeth are also described.Type: GrantFiled: May 30, 2018Date of Patent: July 18, 2023Assignee: Oregon Health & Science UniversityInventors: Luiz Bertassoni, Anthony Tahayeri, Avathamsa Athirasala, Jack L. Ferracane
-
Patent number: 11701324Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.Type: GrantFiled: February 19, 2021Date of Patent: July 18, 2023Inventors: Marina Lee Gerton, Brenda K. Mann
-
Patent number: 11684630Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.Type: GrantFiled: November 16, 2020Date of Patent: June 27, 2023Assignee: GLYCOM A/SInventors: Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
-
Patent number: 11685794Abstract: The invention comprises a method of industrial extraction of alginates from brown seaweeds of the family Sargassaceae of the order Fucales, as well as the product resulting from the method. The method includes the following stages: preparation of raw materials, crushing of the algae, pressure boiling of the algae, mixing the boiled algae with water, purification of the diluted algal mass, extraction of alginic acid, washing of the alginic acid, dehydration of the alginic acid, treatment of the alginic acid with sodium hydrogen carbonate, clarification of resultant sodium alginate solution, precipitation of sodium alginate gel, and drying of the sodium alginate gel.Type: GrantFiled: February 14, 2022Date of Patent: June 27, 2023Inventors: Iurii Uss, Sergey Yudin, Denis Turishchev
-
Patent number: 11679123Abstract: The invention provides a pharmaceutical composition of hyaluronic acid comprising repeating units of a disaccharide comprising glucuronic acid and N-acetylglucosamine, wherein a portion of the N-acetyl groups of the N-acetylglucosamine have been independently replaced with a group of the formula —N—C(O)—(C2-C4)-alkyl for treating hyperuicemia and gouty arthritis. Studies show that this composition is promising as an anti-gout therapeutic agent, which combines both anti-inflammatory actions as well as anti uracemic effects.Type: GrantFiled: March 7, 2019Date of Patent: June 20, 2023Assignees: Queen's University at Kingston, Jilin UniversityInventors: Yin Gao, Tassos Anastassiades
-
Patent number: 11672815Abstract: Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.Type: GrantFiled: February 2, 2021Date of Patent: June 13, 2023Assignee: CUPIONE CO., LTD.Inventors: Siyoung Yang, Jimin Jeon, Li-Jung Kang, Chanmi Cho
-
Patent number: 11642366Abstract: Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.Type: GrantFiled: June 3, 2019Date of Patent: May 9, 2023Assignee: GLYCOMIRA THERAPEUTICS, INC.Inventors: Won Yong Lee, Abigail Pulsipher, Thomas P. Kennedy, Justin Rodney Savage, Glenn Prestwich
-
Patent number: 11642357Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solation or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.Type: GrantFiled: December 10, 2021Date of Patent: May 9, 2023Assignee: SYNARTRO ABInventors: Bengt Lindqvist, Rune Ringom
-
Patent number: 11627752Abstract: The present invention relates to a method for producing a flavour composition comprising providing a slurry of yeast cell walls and contacting the slurry of yeast cell walls with a glucanase and with an endoprotease, followed by separating a liquid fraction by solid/liquid separation to provide the liquid flavour composition.Type: GrantFiled: March 8, 2022Date of Patent: April 18, 2023Assignee: DSM IP ASSETS B.V.Inventors: Bernadette Theresia Morel, Marco Alexander Van Den Berg
-
Patent number: 11617763Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).Type: GrantFiled: August 6, 2018Date of Patent: April 4, 2023Assignee: PARADIGM BIOPHARMACEUTICALS LTDInventors: Ravi Krishnan, Paul Rennie
-
Patent number: 11576399Abstract: The present invention provides frozen confectionery (sherbet and frozen confectionery containing ice) containing a specific amount of isomaltodextrin that is easy to loosen without affecting a flavor.Type: GrantFiled: May 15, 2018Date of Patent: February 14, 2023Assignee: LOTTE CO., LTD.Inventors: Junko Todo, Naoya Akiyama
-
Patent number: 11564880Abstract: The invention relates to a cosmetic active ingredient comprising at least one Metschnikowia reukaufii extract, and the use of same for the cosmetic treatment of the skin, in particular for improving the radiance of the complexion by acting on the skin microbiota. The active ingredient is effective on mature skin. The invention also concerns compositions comprising the cosmetic active ingredient and a cosmetic method for treating the skin using these compositions.Type: GrantFiled: January 30, 2019Date of Patent: January 31, 2023Assignee: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUEInventor: Jean Paufique
-
Patent number: 11547135Abstract: Disclosed are nutraceutical formulations, and methods of using these nutraceutical formulations for the mitigation of chronic malnutrition in an infant, wherein the infant is breast feeding from a lactating mother ingesting one or more of said nutraceutical formulations in accordance with a prescribed regimen.Type: GrantFiled: September 18, 2019Date of Patent: January 10, 2023Inventors: Glenn H. Sullivan, Guillermo E. Sanchez
-
Patent number: 11541068Abstract: The invention relates to human milk oligosaccharides (HMO) and its use in treatment of autism spectrum disorder (ASD).Type: GrantFiled: May 24, 2018Date of Patent: January 3, 2023Assignee: Glycom A/SInventors: Bruce McConnell, Louise Kristine Vigsnæs
-
Patent number: 11541067Abstract: A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful for the treatment of brain-gut disorders like autism, stress, anxiety, and depressive disorders, are disclosed. Methods of treatment of colon cancer and liver damage are also disclosed.Type: GrantFiled: May 24, 2018Date of Patent: January 3, 2023Assignee: Glycom A/SInventors: Louise Kristine Vigsnæs, Bruce McConnell
-
Patent number: 11540549Abstract: The present disclosure provides soluble dietary fibers, food and beverage products including them, and methods for using them. In one aspect, the disclosure provides soluble dietary fiber having a fiber content of at least 97% as measured by AOAC 2001.03 and a DP1+DP2 content of no more than 3 wt % (e.g., no more than 2 wt %) on a dry solids basis. The soluble dietary fiber can be useful in variety of food and beverage applications including fermented foods and beverages like beer and sake.Type: GrantFiled: January 23, 2020Date of Patent: January 3, 2023Assignee: Tate & Lyle Solutions USA LLCInventors: Mark Bahar, Juhi Tomar, Mervyn de Souza, Annette Evans
-
Patent number: 11540546Abstract: Disclosed are nutraceutical formulations, including extracts comprising the hydrophilic and lipophilic fractions of stabilized rice bran. Also disclosed are methods for using said nutraceutical formulations for the management or remediation of conditions related to type II diabetes in humans, including methods for decreasing HbA1c and fasting glucose blood concentrations, and for increasing serum fasting insulin levels.Type: GrantFiled: September 17, 2019Date of Patent: January 3, 2023Inventors: Glenn H. Sullivan, Guillermo E. Sanchez
-
Patent number: 11535683Abstract: Compositions comprising oxidized dextran compounds are disclosed herein. Oxidized dextran compounds are produced by contacting dextran under aqueous conditions with at least one N-oxoammonium salt, at least one periodate compound, and/or at least one peroxide compound.Type: GrantFiled: September 23, 2020Date of Patent: December 27, 2022Assignee: NUTRITION & BIOSCIENCES USA 4, INC.Inventors: Jayme L. Paullin, Rakesh Nambiar
-
Patent number: 11524025Abstract: The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.Type: GrantFiled: June 1, 2020Date of Patent: December 13, 2022Assignee: NutriLeads B.V.Inventors: Maria Tzoumaki, Ruud Albers
-
Patent number: 11504416Abstract: A food supplement comprising a therapeutically effective amount of a composition is described. The composition includes hydrolyzed collagen, hyaluronic acid, ascorbic acid, and glucosamine hydrochloride. The composition may also include a cannabinoid or prodrug, vitamin C, vitamin D, and/or vitamin E. The therapeutically effective amount of the composition is effective in alleviating at least one symptom of a degenerative joint disease in a human or may be used for the prophylaxis of the degenerative joint disease in the human. The at least one symptom of the degenerative joint disease in the human includes joint pain and mobility pain.Type: GrantFiled: July 16, 2020Date of Patent: November 22, 2022Assignee: PAW POWER, INC.Inventor: Anja Skodda
-
Patent number: 11497763Abstract: A compound that includes a dextran backbone having at least one C-type lectin targeting moieties attached thereto. Also disclosed are embodiments of the compound that include at least one therapeutic agent and/or at least one detection label attached to the dextran backbone. The compound may be effective for treatment of Corona Covid-19 (SARS-covid-2) virus, its variants and other related viral diseases, and disorders. Further disclosed are methods for diagnosing and treating diseases and/or disorders directly using the disclosed compounds.Type: GrantFiled: June 30, 2021Date of Patent: November 15, 2022Assignee: Physis International LLCInventor: Frederick Oliver Cope
-
Patent number: 11470860Abstract: Use of a sophorolipid in the preparation of a feed supplement for the improvement of feed efficiency in an animal. A feed supplement comprising a sophorolipid and lysolecithin mix is also provided for improving the feed conversion rate of an animal.Type: GrantFiled: March 1, 2017Date of Patent: October 18, 2022Assignee: PATHWAY INTERMEDIATES LIMITEDInventors: David John Garnett, Lloyd Cooper
-
Patent number: 11458122Abstract: Some embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. Other embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Still other embodiments of the invention include methods for treating an animal for MS or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Additional embodiments of the invention are also discussed herein.Type: GrantFiled: August 8, 2018Date of Patent: October 4, 2022Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Xuelian He, Qing Lu, Liguo Zhang
-
Patent number: 11458202Abstract: The polysaccharide released from the unicellular cyanobacterium Cyanothece sp. CCY 0110 exhibits low cytotoxicity and proves to be suitable for the delivery of macromolecules. The cyanobacterium extracellular polymer disclosed in the present subject-matter, namely a polysaccharide and more in particular an heteropolysaccharide, assembles with proteins into a new phase with gel-like behaviour and the release kinetics can be modulated (i.e., delayed) by adding divalent cations and/or also exhibits physical and chemical properties typical of a bioemulsifier or a bioflocculant.Type: GrantFiled: September 14, 2020Date of Patent: October 4, 2022Assignee: INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR—IBMCInventors: Rita Gil Vasconcelos Mota, Paula Tamagnini, Luis Miguel Gales Pereira Pinto, José Pedro Santos Leite, Sara Isabel Macedo Bernardes Pereira
-
Patent number: 11452748Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.Type: GrantFiled: June 21, 2019Date of Patent: September 27, 2022Assignees: Research Institute at Nation Children's Hospital, Ohio State Innovation FoundationInventors: Steven D. Goodman, Lauren O. Bakaletz, Gail Besner, Michael Bailey
-
Patent number: 11452736Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.Type: GrantFiled: November 30, 2018Date of Patent: September 27, 2022Inventors: Louise Kristine Vigsnæs, Bruce McConnell
-
Patent number: 11446326Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.Type: GrantFiled: July 24, 2019Date of Patent: September 20, 2022Assignee: ARC Medical DevicesInventors: Christopher Michael Kevin Springate, Sailesh Haresh Daswani
-
Patent number: 11446235Abstract: The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles, looseness and dryness), and scalp issues (e.g., dandruff, seborrheic dermatitis and hair loss). In preferred embodiments, the compositions according to the subject invention comprise biological amphiphilic molecules produced by microorganisms.Type: GrantFiled: April 30, 2018Date of Patent: September 20, 2022Assignee: LOCUS IP COMPANY, LLCInventors: Sean Farmer, Ken Alibek, Sharmistha Mazumder
-
Patent number: 11441131Abstract: Heparosan synthase variants having improved expression levels, enhanced thermal stability, and/or reduced reverse glycosylation activity are provided. Methods for making oligosaccharides and polysaccharides, including heparin analogs and heparan sulfate analogs, are also described.Type: GrantFiled: June 19, 2020Date of Patent: September 13, 2022Assignee: The Regents of the University of CaliforniaInventors: Xi Chen, Lan Na, Hai Yu, John B. McArthur
-
Patent number: 11433158Abstract: An absorbent article comprising a topsheet, a backsheet joined to the topsheet, and an absorbent core positioned intermediate the topsheet and the backsheet and comprising a core absorbent material, in which the core absorbent material comprises superabsorbent polymers with a bio-based content from about 5% to about 100% using ASTM D6866-10, method B and the absorbent article comprises a polyolefin content of at least about 90% by weight, based on a total weight of the absorbent article excluding the core absorbent material.Type: GrantFiled: December 3, 2018Date of Patent: September 6, 2022Assignee: The Procter & Gamble CompanyInventors: Paul Thomas Weisman, Eric Patton Weinberger
-
Patent number: 11432578Abstract: A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2?-fucosyllactose (2?FL), 3?-O-sialyllactose (3?-SL), 6?-O-sialyllactose (6?-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.Type: GrantFiled: December 15, 2016Date of Patent: September 6, 2022Assignee: GLYCOM A/SInventors: Bruce McConnell, Louise Kristine Vignæs
-
Patent number: 11426427Abstract: The invention relates to an isotonic crystalloid aqueous solution of the type containing Na+, K+ and Cl?, and to the use thereof as a vasodilator.Type: GrantFiled: July 18, 2017Date of Patent: August 30, 2022Inventor: Lara Oller Duque
-
Patent number: 11426424Abstract: A method for treatment of vaginal disorders may include: administering topically to a subject in need thereof a therapeutically effective amount of molecular oxygen and hyaluronic acid. The molecular oxygen may be in gaseous form. The vaginal disorders may be selected between vaginal dryness and vulvovaginal atrophy.Type: GrantFiled: June 20, 2018Date of Patent: August 30, 2022Assignee: CARESS FLOW S.r.l.Inventor: Leone Condemi